Tirzepatide (Mounjaro)

FDA Approved

Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes

Weight: 4,813.55 Da
Half-life: ~5 days (120 hours)
Chain: 39 amino acids
8 studies
2025 latest
4 recent
FDA Approved
Dose 2.5mg starting, titrate up to 5-15mg weekly
Frequency Once weekly (same day each week)
Cycle Ongoing therapy as prescribed
Storage Pen: 2-8°C before first use, room temp up to 21 days after. Compounded: 2-8°C
Accumulation Plotter

Community Research

Join others researching Tirzepatide — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.

Mechanism of Action

Dual agonist targeting both GIP and GLP-1 receptors, producing glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression, and central satiety signaling via hypothalamic pathways.

01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise

Molecular Data

Molecular Weight
4,813.55 Da
Chain Length
39 amino acids
Type
Dual GLP-1/GIP agonist
Amino Acid Sequence
One-letter: HUEGTFTSDVSSYLEGQAAKEFIAWLVRGRGGGGGPSKKKKKK
H₂N
H 1
O ‖ C
N
U 2
O ‖ C
N
E 3
O ‖ C
N
H
G 4
O ‖ C
N
T 5
O ‖ C
N
F 6
O ‖ C
N
T 7
O ‖ C
N
S 8
O ‖ C
N
D 9
O ‖ C
N
V 10
O ‖ C
N
S 11
O ‖ C
N
S 12
O ‖ C
N
Y 13
O ‖ C
N
L 14
O ‖ C
N
E 15
O ‖ C
N
H
G 16
O ‖ C
N
Q 17
O ‖ C
N
A 18
O ‖ C
N
A 19
O ‖ C
N
K 20
O ‖ C
N
E 21
O ‖ C
N
F 22
O ‖ C
N
I 23
O ‖ C
N
A 24
O ‖ C
N
W 25
O ‖ C
N
L 26
O ‖ C
N
V 27
O ‖ C
N
R 28
O ‖ C
N
H
G 29
O ‖ C
N
R 30
O ‖ C
N
H
G 31
O ‖ C
N
H
G 32
O ‖ C
N
H
G 33
O ‖ C
N
H
G 34
O ‖ C
N
H
G 35
O ‖ C
N
P 36
O ‖ C
N
S 37
O ‖ C
N
K 38
O ‖ C
N
K 39
O ‖ C
N
K 40
O ‖ C
N
K 41
O ‖ C
N
K 42
O ‖ C
N
K 43
COOH
His
1

Histidine

Position 1

Aib
2

Aminoisobutyric Acid

Position 2

Glu
3

Glutamic Acid

Position 3

Gly
4

Glycine

Position 4

Thr
5

Threonine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Ser
8

Serine

Position 8

Asp
9

Aspartic Acid

Position 9

Val
10

Valine

Position 10

Ser
11

Serine

Position 11

Ser
12

Serine

Position 12

Tyr
13

Tyrosine

Position 13

Leu
14

Leucine

Position 14

Glu
15

Glutamic Acid

Position 15

Gly
16

Glycine

Position 16

Gln
17

Glutamine

Position 17

Ala
18

Alanine

Position 18

Ala
19

Alanine

Position 19

Lys
20

Lysine

Position 20

Glu
21

Glutamic Acid

Position 21

Phe
22

Phenylalanine

Position 22

Ile
23

Isoleucine

Position 23

Ala
24

Alanine

Position 24

Trp
25

Tryptophan

Position 25

Leu
26

Leucine

Position 26

Val
27

Valine

Position 27

Arg
28

Arginine

Position 28

Gly
29

Glycine

Position 29

Arg
30

Arginine

Position 30

Gly
31

Glycine

Position 31

Gly
32

Glycine

Position 32

Gly
33

Glycine

Position 33

Gly
34

Glycine

Position 34

Gly
35

Glycine

Position 35

Pro
36

Proline

Position 36

Ser
37

Serine

Position 37

Lys
38

Lysine

Position 38

Lys
39

Lysine

Position 39

Lys
40

Lysine

Position 40

Lys
41

Lysine

Position 41

Lys
42

Lysine

Position 42

Lys
43

Lysine

Position 43

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Weight Loss
Severe Obesity Management most effective

Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.

Metabolic Syndrome Reversal most effective

Improvements in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers.

Body Composition Optimization effective

Preferentially reduces visceral adipose tissue while preserving lean muscle mass with resistance training.

Diabetes
Type 2 Diabetes Management most effective

Superior HbA1c reduction of 1.5-2.4% in clinical trials.

Insulin Resistance Improvement effective

Improves insulin sensitivity across diverse populations.

Beta Cell Preservation effective

May help preserve and restore pancreatic beta cell function.

Cardiovascular
MACE Reduction effective

26% reduction in major adverse cardiovascular events demonstrated in SURPASS-CVOT trial.

Blood Pressure Reduction effective

Systolic and diastolic blood pressure reductions of 8-12 mmHg.

Lipid Profile Improvement moderate

Triglyceride improvements of 20-30%, HDL enhancement, and apolipoprotein B reduction.

Dosing Protocols

Once-weekly subcutaneous injection. Can be taken any time of day, with or without food. Injection sites include thigh, abdomen (2+ inches from navel), or upper arm.

GoalDoseFrequencyRoute
Weight loss initiation2.5mgOnce weekly x 4 weeksSubQ injection
Weight loss progression5mgOnce weeklySubQ injection
Weight loss optimization7.5-10mgOnce weeklySubQ injection
Maximum weight loss12.5-15mgOnce weeklySubQ injection
Diabetes management (mild)5-7.5mgOnce weeklySubQ injection
Diabetes management (severe)10-15mgOnce weeklySubQ injection

Reconstitution Instructions

Materials Needed:
  • Tirzepatide lyophilized powder vial (or pre-filled pen)
  • Bacteriostatic water for injection
  • Insulin syringes (0.5ml or 1ml with fine needle)
  • Alcohol prep pads
  • Sterile work surface
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial tops with alcohol wipes, allow air drying
  3. 3 Calculate reconstitution volume
  4. 4 Draw bacteriostatic water carefully into syringe
  5. 5 Insert needle at 45-degree angle against glass wall
  6. 6 Inject water slowly down vial side to prevent foaming
  7. 7 Gently swirl—never shake vigorously
  8. 8 Allow 2-3 minutes for clearing if cloudiness appears
  9. 9 Final solution must be completely clear and colorless
  10. 10 Label with date and concentration
  11. 11 Store at 2-8°C, use within 28 days

Interactions

!
Semaglutide
Both are GLP-1 agonists—combining increases hypoglycemia and severe GI side effect risk.
avoid
!
Liraglutide
Another GLP-1 agonist—dual therapy contraindicated due to additive effects.
avoid
~
Insulin
May require significant insulin dose reduction due to improved sensitivity.
monitor
++
Metformin
Complementary mechanisms for diabetes management and weight loss.
synergistic
+
CJC-1295
Growth hormone support may help preserve muscle mass during weight loss.
compatible
+
Ipamorelin
May help maintain metabolic rate and muscle preservation.
compatible
+
BPC-157
No known interactions, may support gut health and reduce GI effects.
compatible
+
5-Amino-1MQ
NNMT inhibition may complement GLP-1 effects for metabolic optimization.
compatible

What to Expect

Day 1-3
Appetite reduction begins
Week 1-2
Improved blood sugar control (diabetics), mild nausea common
Week 2-4
Initial weight loss begins; GI side effects typically improve
Ongoing
1-3 lbs weight loss per week during active phase
Week 16-24
Peak weight loss effects observed

Side Effects & Safety

Common Side Effects

  • Nausea (mild to moderate, first 2-4 weeks)
  • Appetite reduction
  • Possible fatigue during adaptation
  • Diarrhea or constipation
  • Reduced food cravings

Stop Signs - Discontinue if:

  • Severe/persistent abdominal pain (pancreatitis risk)
  • Neck lumps, hoarseness, difficulty swallowing (thyroid concerns)
  • Severe nausea/vomiting preventing adequate nutrition
  • Severe hypoglycemic signs (confusion, sweating, rapid heartbeat)
  • Kidney problems (decreased urination, swelling)
  • Severe allergic reactions (rash, breathing difficulty)
  • Suicidal thoughts or severe depression
  • Gallbladder problems (severe upper right pain)
  • Dehydration from persistent vomiting

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Pregnancy or breastfeeding
  • History of pancreatitis

Quality Checklist

Good Signs

  • White to off-white lyophilized powder without clumping
  • Clear, colorless reconstituted solution
  • Intact vial seal with visible mg dosage labeling and batch numbers
  • Proper storage maintenance at 2-8°C, protected from light

Warning Signs

  • Compounded versions without proper quality control

Bad Signs

  • Powder clumping, discoloration, or yellow/brown appearance
  • Persistent cloudiness after reconstitution
  • Unusual crystallization patterns

References

  • Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
    Jastreboff, A.M., et al.
    New England Journal of Medicine (2022)

    Landmark phase 3 trial: 15mg weekly achieved 22.5% weight loss vs 2.4% placebo over 72 weeks. Weight reduction of ≥20% achieved in 57% of 15mg recipients.

  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
    Frías, J.P., et al.
    New England Journal of Medicine (2021)

    Tirzepatide was noninferior and superior to semaglutide 1mg for HbA1c reduction and weight loss in type 2 diabetes. The 15mg dose achieved nearly twice the weight loss of semaglutide.

  • Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
    Garvey, W.T., et al.
    The Lancet (2023)

    15mg dose achieved 15.7% weight loss over 72 weeks with significant cardiometabolic improvements. 79-83% of tirzepatide recipients achieved ≥5% weight loss vs 32% placebo.

  • Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)
    Nicholls, S.J., et al.
    New England Journal of Medicine (2025)

    Tirzepatide was noninferior to dulaglutide for MACE (composite of CV death, MI, or stroke). Several secondary endpoints favored tirzepatide, including reduced all-cause mortality after 4-year median follow-up.

  • Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 3-Year Extension)
    Jastreboff, A.M., et al.
    New England Journal of Medicine (2025)

    Three years of tirzepatide resulted in sustained weight reduction of up to 19.7% (15mg) and 93% lower risk of progression to type 2 diabetes vs placebo (HR 0.07).

  • Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
    Packer, M., et al.
    New England Journal of Medicine (2024)

    Tirzepatide reduced the composite of CV death or worsening heart failure by 38% (HR 0.62) vs placebo over median 104 weeks. Improved health status scores and 6-minute walk distance.

  • Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
    Aronne, L.J., et al.
    New England Journal of Medicine (2025)

    Head-to-head comparison: tirzepatide achieved 20.2% weight loss vs 13.7% with semaglutide at 72 weeks. Tirzepatide was superior for body weight and waist circumference reduction.

  • Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
    Malhotra, A., et al.
    New England Journal of Medicine (2024)

    Tirzepatide significantly reduced AHI with resolution of OSA in approximately 50% of participants. Also reduced body weight, hypoxic burden, hsCRP, and systolic blood pressure.

Related Peptides

Ipamorelin compatible

May help maintain metabolic rate and muscle preservation.

BPC-157 compatible

No known interactions, may support gut health and reduce GI effects.

5-Amino-1MQ compatible

NNMT inhibition may complement GLP-1 effects for metabolic optimization.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.